Procedural and in-hospital outcomes for all consecutive patients treated between May 2007 and November 2011 with Edwards SAPIEN THV (Edwards Lifescience, Irvine, CA) as part of the PARTNER Background-Paravalvular regurgitation (PVR) is common after transcatheter aortic valve replacement (TAVR) and may be associated with adverse outcomes. Postdilatation (PD) has been proposed to treat PVR without being formally studied. We performed a study to evaluate the safety and efficacy of PD after balloon expandable TAVR. Methods and Results-Consecutive cases of TAVR were reviewed for clinical outcomes. Procedural transesophageal echocardiography imaging was reviewed for a subgroup of consecutive patients. PVR areas seen on a short-axis view were measured immediately after deployment, after PD, and at the completion of the study. Stent dimensions measured using angiography and the Paieon's C-THV system pre-and post-PD were compared. Between May 2007 and November 2011, 259 patients underwent TAVR at our institution. PD was performed in 106 patients (41%). These patients had larger annulus, lower cover-index; more often had transfemoral access and implantation of a 26 mm valve. There was a nonsignificant greater rate of cerebrovascular events in PD patients. There was no significant difference in major aortic injury and permanent pacemaker implantation rates between groups. TTE studies were reviewed in 58 patients (35 with PD and 23 without PD 
T ranscatheter aortic valve replacement (TAVR) has emerged as a new alternative treatment for patients with severe aortic stenosis, who are at high risk or deemed inadequate candidates for conventional surgical aortic valve replacement.
1,2 Paravalvular regurgitation (PVR) is a common finding after TAVR. Aortic regurgitation has been reported in 80% to 96% of TAVR cases. 1, [3] [4] [5] [6] In most cases, the degree of regurgitation is at most mild; however, moderate and severe degrees of aortic regurgitation are found in 7% to 24% of patients. 1, [3] [4] [5] [6] Multiple studies have demonstrated that moderate and severe degrees of regurgitation are associated with worse clinical outcomes [7] [8] [9] whereas the 2-year follow-up of the Placement of Aortic Transcatheter Valves (PARTNER) trial suggested that even mild PVR is associated with increased mortality. 10 Smaller cover index, 3 annulus eccentricity, 11 and the degree and distribution of leaflet calcifications 12 have been identified as risk factors for PVR. Postdilatation (PD) of balloon expandable valves after implantation has been proposed as an effective method to reduce PVR recognized during the index procedure. 11, 13 However, potential risks of PD, including transcatheter heart valve (THV) migration or injury, trauma to the conduction system, rupture of the membranous septum or aorta and cerebrovascular embolism, may outweigh the potential benefits from reduction in aortic regurgitation. The aim of this study was to evaluate the efficacy of PD of balloon-expandable THVs at reducing PVR and its clinical safety (neurological events, aortic injuries, conduction blocks) when used in cases with more than mild PVR documented immediately after implantation.
and PARTNER 2 trials were reviewed both prospectively and retrospectively. Information on PD was collected retrospectively from chart and imaging review for the period between 2007 and August 2010, and prospectively after August 2010. PD was performed in cases where PVR was qualitatively more than mild, by transesophageal echocardiography (TEE), immediately after THV implantation. Although volumetric and 3-dimensional analysis of regurgitant volumes were completed after the final dilatation and at the end of the study, the rapid intraprocedural assessment required before decisions about PD did not allow the quantitative methodology to be used. Decisions were based on assessment of the severity of regurgitation in the short-axis view. Using simultaneous multiplane imaging (3-dimensional TEE technology) with the long-axis view as the primary view, we could precisely and consistently localize the region just beneath the stent, thus, reducing variability not only within each case, but also between cases. The balloon was systematically left in the ascending aorta during TEE evaluation, avoiding a second transit of the balloon in the arch. PD was performed with the same balloon used for THV implantation under rapid-pacing runs similar to those used during initial valve deployment. PD was performed using either the same volume or with an additional 0.5 to 2 cc in the Atrion syringe. The balloon was positioned slightly more toward the apex for PD. Postdeployment angiography is not done routinely in our institution.
Echocardiographic Data
Two experienced, unblinded, echocardiographers reviewed a subgroup of consecutive patients with adequate TEE color Doppler imaging of the region just apical to the proximal edge of the THV. All TEE studies were performed using an iE33 xMATRIX system using the X7-2t TEE transducer capable of simultaneous multiplane imaging of real-time images (Phillips, Andover, MA). The PVR area was quantified using a short-axis view just below the stent of the valve, in the left-ventricular outflow tract. This level was confirmed by using simultaneous imaging of the long-axis view (between 120 and 140 degrees) as the primary plane ( Figure 1 ) with a 90-degree orthogonal short-axis view. At this level, the short-axis areas of the jets were measured, and the sum of the jet areas was used as the total PVR area. This imaging plane was obtained at 3 time points: immediately after deployment (PVR 1 ), after PD (PVR 2 only for the PD group), and at the completion of the imaging study (PVR 3 ; Figure 1 ). Central intraprosthetic regurgitation was also evaluated at the completion of the study.
Angiographic Data
The Paieon's C-THV system, used as adjunctive imaging to fluoroscopy to find coplanar views and to help positioning of the THV, was used to quantify postdeployment dimensions of the stent. In consecutive patients who had Paieon's C-THV adjunctive imaging, the inflow (IF), outflow (OF), and minimal diameters of the stent were measured immediately after deployment as well as after PD (Figure 2 ).
Definitions and End Points
Neurological events were defined using valve academic research consortium definitions.
14 Cover-index is defined as: 100×([THV diameter-TEE annulus diameter]/THV diameter). 3 Clinical end points for the current analysis included 30-day mortality, in-hospital stroke or transient ischemic attack, procedural related major aortic injury (aortic dissection, aortic wall hematoma, or annulus/aortic rupture) and need for new permanent pacemaker during the index hospitalization. Two cardiologists who were unaware of the status of PD adjudicated all clinical events. In case of discrepancy, disagreements were resolved by consensus between the 2 cardiologists. All patients with neurological events were evaluated by neurologists and had neuroimaging tests done. 
Results
Between May 2007 and November 2011, 259 patients with severe aortic stenosis underwent transapical or transfemoral TAVR with Edwards-SAPIEN THV as part of the PARTNER I and PARTNER II trials at our institution (Columbia University Medical Center/NewYork Presbyterian Hospital, New York City, NY). PD was performed in 106 patients (41%) for more than mild PVR seen on TEE imaging immediately after implantation. PD patients were taller and heavier, more often were male with lower STS scores than patients who did not receive PD (Table 1) . They also had larger annular diameter on intraprocedural TEE, lower cover-index and more often had transfemoral rather than transapical access. The proportion of 26 mm valve versus 23 mm valve and of SAPIEN-XT versus SAPIEN valves was significantly higher in patients with PD (Table 2) .
Procedural Results and Clinical Outcomes
No valve embolization occurred during PD. No patient required implantation of a second THV after PD. Multiple PD was performed in 4 cases. There was no statistically significant difference between the 2 groups in the incidence of neurological events, although they were more frequent in patients with PD (Table 3) . Seven cerebrovascular events were observed during the index hospitalization, all within 48 hours of TAVR. One major stroke, 3 minor strokes, and 1 transient ischemic attack occurred in patients with PD, whereas 1 major stroke and 1 transient ischemic attack occurred in patients without PD. One stroke occurred in a patient with multiple PDs. Permanent pacemaker implantation during the index hospitalization was not significantly different between the 2 groups (Table 3) . Major aortic injuries were rare and occurred at a similar rate between both groups with no aortic/annulus
WHAT IS KNOWN
• Significant paravalvular regurgitation after transcatheter aortic valve replacement is associated with increased mortality.
• Calcifications, undersized prosthesis, and malposition are causes of paravalvular regurgitation.
WHAT THE STuDy ADDS
• Additional postdilatation can reduce the magnitude of paravalvular regurgitation.
• Spontaneous regression of paravalvular regurgitation occurs within minutes after transcatheter aortic valve replacement.
• Postdilatation may be associated with increased risk of cerebrovascular events.
rupture observed in this cohort of patients. There was a trend toward higher 30-day mortality in patients who did not receive PD (Table 3) .
Echocardiographic Outcomes
A subgroup of 58 consecutive patients with adequate TEE imaging were reviewed and analyzed; 35 with PD (PD+) and 23 without PD (PD−). Baseline characteristics of these patients are presented in Table 4 . Similar to what was seen in the larger clinical cohort, patients in the PD+ group had larger annulus and lower cover-index. PVR 1 was significantly larger in the PD+ group (Table 4) 
Angiographic Outcomes
Additional stent expansion after PD was assessed using the Paieon's C-THV system in 24 cases (20 cases with 26 mm valve and 4 cases with 23 mm valve). There was a significant increase in the OF, IF, and minimal diameters after PD of 26 mm valves. The changes were not statistically significant for the 23 mm valves (Table 5 ). There was a greater expansion in the IF and OF diameters compared with the minimal diameter.
Discussion
This is the second study to demonstrate that PD of balloonexpandable THV can effectively reduce postdeployment PVR, whereas simultaneously increasing stent expansion. Furthermore, we have shown that judicious use of PD for greater than mild PVR is not associated with excess morbidity or mortality, although some concerns regarding cerebral embolism deserve comment. When it occurs, PVR is a significant cause of nonstructural prosthetic valve dysfunction. The anatomic positioning and resultant physiology of THV, however, are different from surgical valves. After surgical aortic valve replacement, most commonly PVR is attributable to infection, suture dehiscence, or fibrosis and calcification of the native annulus, resulting in inadequate contact or gaps between the sewing ring and annulus. Because THVs do not have a sewing ring traditional dehiscence cannot occur. For balloon-expandable THV, significant PVR most commonly results from incomplete prosthesis apposition to the native annulus attributable to retained biological material of the native valve, ridges of calcium, 12, [15] [16] [17] or annular eccentricity. 11 In addition, undersizing of the device, 3 and mal-positioning of the valve, can cause problematic PVR. 18 PD has been used by many operators to decrease PVR. Although its utility is seemingly intuitive, there are scarce data supporting its safety. 11, 19 This study evaluated the clinical outcomes of 259 consecutive patients treated with Edwards-SAPIEN and Edwards SAPIEN-XT THV. PD was performed in 41% of the cases. This proportion of PD is significantly higher than the 19% published by Tay et al, 19 the 5% reported by Unbehaun et al, 11 and the 28% of Nombela-Franco et al 13 and reflects a lower threshold for PD in our institution. We observed a trend for lower 30-day mortality in patients who underwent TAVR with PD. This observation is most likely multifactorial and not directly related to the PD status. Patients without PD had higher STS score and had more often transapical access. In our cohort, there was a trend for higher 30-day mortality in patients with transapical access compared with those with transfemoral (9.0% versus 2.9%; odds ratio [95% confidence interval], 3.26 [1.03-10 .28]; P=0.067). Patient selection bias related to per-procedural events may also have had significant influence on mortality of each group, because the majority of patients who had a serious complication during or after valve deployment (aortic dissection/hematoma, LV perforation, severe central regurgitation) did not have PD.
Recent data have suggested that even mild PVR is associated with increased mortality. 10 This study brings evidence to support the use of PD when suboptimal results are present immediately after implantation. On the other hand, the occurrence of a disabling stroke after TAVR has emerged as a major concern.
2,20,21 Trans-cranial Doppler studies have shown that microembolic events occur during balloon valvuloplasty, manipulation of the prosthesis across the valve and valve deployment. 22, 23 The impact of PD was not assessed in these trials but could theoretically be associated with embolic events. We observed a statistically nonsignificant but higher rate of neurological events in patients with PD. Canadian investigators reported similar findings in another single center experience. In this study Tay et al 19 observed a nonsignificant higher incidence of PD in patients with a cerebrovascular event. The incidence of PD was 26% in patients with cerebrovascular events versus 18% in patients with no event (P=0.43). Similarly, Grube et al 24 demonstrated a reduction in stroke rate when implanting a self-expandable THV without predilatation, hence limiting manipulations at risk for debris embolization. However, their stroke rate, even without predilatation was higher than what we observed in our PD patients, whereas their stroke rate with predilatation was higher than what was reported in all major registries. 20 More recently, Nombela-Franco et al 13 demonstrated a significant increase in neurological event associated with PD. They were able to demonstrate that an increase in calcification of the valve and PD were 2 independent predictors of stroke. Significant differences in our populations should be discussed. In their study, the cover-index was similar for patients with and without PD, suggesting a cause of PVR different than in our study. Valvular calcification and asymmetry of valve opening are recognized causes of PVR 12, [15] [16] [17] and may increase embolic events during TAVR. Calcification was a predictor for the need of PD in their study. Unfortunately, we did not evaluate systematically the calcium burden using computed tomography. In our cohort, only 1 major stroke occurred in each group, whereas all other events were minor strokes and transient ischemic attacks. A greater proportion of patients with annulus/prosthesis mismatch as a cause of PVR, which is not clearly associated with an increased risk of stroke, may explain the lower neurological event rate in our study. Despite all these studies, it is still unclear whether the PD per se is responsible for an increase in stroke rate rather than being an association with high calcium burden, which would be AVA indicates aortic valve area; BSA, body surface area; PD, postdilatation; PVR, paravalvular regurgitation; PVR 1 , PVR after valve deployment; PVR 2 , PVR after PD; PVR 3 , PVR at completion of imaging study; and THV, transcatheter heart valve. causing more embolic events. Based on these observations, it is however wise to attempt to minimize the need for PD and use it with caution. In our study, PD was not associated with an increased frequency of major aortic injuries and new permanent pacemaker implantations. Although we demonstrated spontaneous regression of mild PVR seen in the first minutes after valve implantation, we also observed that PD is effective at reducing more than mild PVR occurring immediately after THV deployment. The reduction attributable to PD was 3 times the spontaneous reduction rate. By limiting the additional amount of volume in the balloon for PD to 1 cc in the vast majority of cases, we did not observe an increase in central regurgitation despite a significant increase in stent expansion. This observation is different than what was reported by Unbehaun et al 11 , where they postdilated 18 cases with 1 to 3 additional cc with the need to implant a second valve in 10 (56%) of these patients, most likely because of significant central regurgitation. Our angiographic data support the hypothesis that PVR is reduced because of greater stent expansion, hence, greater coverage of the annulus area, after PD. The greater expansion seen at the IF compared with the mid-portion of the stent may also change the morphology of the stent and change the pattern of PVR. The additional stent expansion seen is consistent with the observations from Giri et al 25 from 5 patients, where a second THV was implanted within the first THV. The low number of patients with angiographic evaluation of stent expansion, however, precludes from more detailed analysis. Greater stent expansion could be the result of the redilatation itself or the additional volume. Recent publications have linked the pattern of calcification seen on computed tomography scan with PVR. 12 It is possible that some pattern of calcification have better response to PD than other. As observed in other studies, 3 the cover-index seems to be a good predictor of PVR and the need for PD. Oval-shaped annulus has also been linked with greater PVR. 11 The use of either 3-dimensional TEE or computed tomography scan may help to choose the appropriate valve size and minimize PVR and possibly the need for PD. Finally, the largest available valve in our study was a 26 mm. The availability of a 29 mm valve would have allowed greater cover-index for patients with an annulus of 24 to 25 mm and may have decreased the need for PD. With better definition of the annulus size using 3-dimensional imaging, it could be reasonable to modify (adding or removing up to 1 mL) the amount of fluid in the delivery system based on the annulus area or perimeter. Future generation THV with expanding biosubstance or tissue skirt to help seal the paravalvular space may further decrease PVR and the need for PD.
Several important limitations of the present analysis should be discussed. This is a retrospective, nonrandomized study. Because of this limitation, this study may overor underestimate the reduction of PVR attributable to PD, and clinical outcome difference between groups may be related to baseline characteristic differences or unmeasured confounders. Whereas the native valve regurgitation quantitative grading scheme has been advocated for the evaluation of prosthetic valve regurgitation, 26 there are scant data to support the use of these parameters after TAVR. Color Doppler evaluation should be performed just below the skirt for paravalvular jets, and at the coaptation point of the leaflets for central regurgitation. In the current study, only the short-axis view below the THV skirt was used to assess PVR immediately after valve implantation. Central regurgitation resulting from malcoaptation of leaflets created by the guide wire may be included in the measurement of PVR, however, this would be true for both groups of patients. Imaging of the substent short-axis view was the most timeeffective method of qualitatively assessing the severity of PVR and expeditiously guiding further therapeutic intervention. For this study, we used the short-axis summed areas of the jets as a semiquantitative assessment of regurgitant severity that could be used before and after PD. This semiquantitative approach can be used as an additional tool to the more accepted methods of quantitation of regurgitation during TAVR. Total PVR jet area in the left-ventricular outflow tract may be influenced by a number of factors: small changes of the sampling location, paravalvular jets impinge the wall of the LV which reduce jet area or may be entrained within the left-ventricular outflow tract leading to rapid jet broadening. Changes in blood pressure can also influence the area of the regurgitation seen in the OF tract. Although we did not record blood pressure at each stage of deployment and PD, lower blood pressure is generally observed immediately after the long pacing runs of valve deployment and PD, and tends to be higher toward the end of the study as the sedation is being weaned. These hemodynamic changes would underestimate rather than overestimate the effect of PD (and spontaneous regression). The magnitude of spontaneous regression for moderate or large PVR jets cannot be determined because all patients with this qualitative severity of regurgitation received a PD. Given the similar degree of spontaneous PVR regression for both groups between the last dilatation and end of study, it seems likely, however, that a larger amount of PVR would have resulted without PD. The number of major clinical events was relatively low in this cohort of patients; hence, the absence of significant difference in event rates may be caused by a lack of power. Using a P value of <0.05 for significance may inflate type I error, and a Bonferroni adjustment could have been considered. Such adjustment would not, however, alter significantly the interpretation of our data.
In conclusion, this is the first study to demonstrate the efficacy and safety of PD at reducing PVR after balloon-expandable TAVR. We recognized a reduction of more than 70% in PVR area with PD that significantly exceeded the observed spontaneous regression rate. In this small study, there was no significant increase in cerebrovascular events, major aortic injuries, or need for permanent pacemaker with PD. Larger clinical studies are needed to confirm these findings, especially to assess the risk of cerebrovascular events. 
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